What is the treatment for pseudogout?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment for Pseudogout

The first-line treatment for acute pseudogout attacks consists of oral NSAIDs, oral colchicine, or systemic corticosteroids, with the choice depending on pain severity, number of joints involved, and patient comorbidities. 1, 2

Acute Attack Management

First-line Options:

  1. NSAIDs:

    • Full FDA/EMA approved dosing (e.g., naproxen, indomethacin)
    • Most effective when started early in the attack
    • Cautions: Avoid in patients with renal impairment, heart failure, peptic ulcer disease, or those on anticoagulants 1, 2
  2. Colchicine:

    • Low-dose regimen: 1.2 mg initially, followed by 0.6 mg one hour later 2
    • Most effective when started within 12 hours of symptom onset
    • Cautions: Adjust dose in renal impairment, avoid with strong P-glycoprotein/CYP3A4 inhibitors 2
  3. Corticosteroids:

    • Oral prednisone (30-35 mg daily for 3-5 days)
    • Intra-articular injection for 1-2 affected joints
    • Intramuscular/intravenous methylprednisolone (0.5-2.0 mg/kg) 1, 2
    • Advantage: Better safety profile than NSAIDs for GI effects 3

For NPO Patients:

  • Intra-articular corticosteroid injection (for 1-2 joints)
  • IV/IM methylprednisolone (0.5-2.0 mg/kg)
  • Subcutaneous ACTH (25-40 IU) 1

For Severe/Refractory Cases:

  • Combination therapy (e.g., colchicine plus NSAIDs) 1
  • Consider IL-1 inhibitors like anakinra in treatment-resistant cases 4, 5

Adjunctive Therapy:

  • Topical ice application 1

Prophylactic Treatment

For patients with recurrent pseudogout attacks:

  • Low-dose colchicine (0.6 mg once or twice daily) has been shown to reduce attack frequency from 3.2 to 1 attacks per patient per year 6
  • Low-dose NSAIDs (e.g., naproxen 250 mg twice daily) with PPI if indicated 1, 2
  • Continue prophylaxis for at least 8 weeks when initiating treatment 2

Lifestyle Modifications

  • Weight loss if obese
  • Limit alcohol consumption (especially beer)
  • Adequate hydration (at least 2 liters daily)
  • Regular moderate physical activity 2

Management of Associated Conditions

  • For hypertension: Consider losartan (has uricosuric effects)
  • For hyperlipidemia: Consider fenofibrate (has modest uricosuric effects) 1, 2
  • Address other metabolic conditions that may be associated with pseudogout

Monitoring and Safety Considerations

  • Assess renal function before initiating therapy
  • Monitor for GI side effects with NSAIDs (dyspepsia, abdominal pain, diarrhea)
  • Watch for colchicine toxicity in patients with renal impairment
  • Evaluate for drug interactions, particularly with colchicine 2

Treatment Algorithm

  1. Assess patient factors: Comorbidities, contraindications, prior response
  2. For mild/moderate attacks (≤6/10 pain, 1-3 small joints or 1-2 large joints): Choose one first-line agent
  3. For severe/polyarticular attacks: Consider combination therapy
  4. For patients with frequent recurrences: Implement prophylactic therapy
  5. For all patients: Implement appropriate lifestyle modifications

Unlike gout, there are currently no medications proven to decrease crystal load in pseudogout, so treatment focuses primarily on managing inflammation and preventing recurrent attacks 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Gout Management Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Treatment and management of pseudogout: insights for the clinician.

Therapeutic advances in musculoskeletal disease, 2012

Research

Colchicine prophylaxis in pseudogout.

The Journal of rheumatology, 1986

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.